Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)* - Concepedia

Concepedia

Publication | Open Access

Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*

DOI Full Paper Access

91

Citations

14

References

2021

Year

Diamant Thaçi, Stefano Piaserico, Richard B. Warren, Aditya K. Gupta, Wendy Cantrell, Zoé Kececioglu Draelos, Peter Foley, Atsuyuki Igarashi, Richard G. Langley, Akihiko Asahina,

British Journal of Dermatology

Abstract

TIL treatment provided sustained disease control over 5 years in week 28 TIL responders and ETN partial responders/nonresponders, with a reassuring safety profile.

References

	Year	Citations

Page 1